Waters Corporation has completed its previously announced combination with the Biosciences & Diagnostic Solutions businesses of Becton, Dickinson and Company. The transaction creates a global life sciences and diagnostics organization with best-in-class technologies and an industry-leading financial outlook.
Waters also appointed Claire M. Fraser, Ph.D., to its Board of Directors, expanding the board to 11 members.
“As we reach this important milestone, I want to welcome our new colleagues to Waters and Dr. Claire Fraser to our Board,” says Flemming Ørnskov, M.D., M.P.H., Chairman, Waters. “Dr. Fraser is an internationally recognized scientist with an extensive background in genomics, infectious diseases, and molecular diagnostics. We will benefit from her expertise and deep knowledge of the business to help oversee our next era of growth and value creation.”
Dr. Fraser is a genome scientist with three decades of experience managing large research institutes. She most recently served as Director of The Institute for Genome Sciences, which she founded in 2007, at the University of Maryland School of Medicine. She also held roles as Professor of Medicine and Microbiology and Immunology. Dr. Fraser earned a B.S. in Biology from Rensselaer Polytechnic Institute in Troy, New York, and a Ph.D. in Pharmacology from the State University of New York at Buffalo.
Working in analytical science?
Register for a FREE Separation Science account to subscribe to the Separation Science Newsletter.
“Our combination with BD’s Biosciences and Diagnostic Solutions businesses marks a pivotal moment for Waters, bringing together world-class scientific expertise across chemistry, physics, and biology, with rich histories of innovation,” remarks Udit Batra, Ph.D., President and Chief Executive Officer, Waters. “As we enter this next chapter, our focus is clear: address our customers’ unmet needs, deliver long-term value for our shareholders, and provide solutions that advance global health. Through our category-defining products and shared culture of innovation, I am confident that together we will accelerate the benefits of pioneering science.”
With the transaction closed, Waters has organized operations into four divisions. The structure reflects a continued focus on high-volume testing in regulated applications and an expansion into adjacent growth markets. The divisions bring together scientific teams that support therapeutic development and manufacturing, food and environmental testing, and specialty diagnostics across molecular, microbiology, and multiplex applications.
This article is a rework of a press release issued by Waters.
